Takuji Shoda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Takuji Shoda has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Yosuke Demizu
National Institute of Health Sciences
6 shared publications Masashi Kato
National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-9501, Japan; School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan
4 shared publicationsMikihiko Naito
National Institute of Health Sciences, 3-25-26 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa 210-9501, Japan
4 shared publications- Genichiro Tsuji
Division of Organic Chemistry, National Institute of Health Sciences, 3-25-26, Tonomachi, Kawasaki, Kanagawa 210-9501, Japan
3 shared publications Hideshi Inoue
School of Life Sciences, Tokyo University of Pharmacy and Life Sciences, 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan
3 shared publications- Masaaki Kurihara
National Institute of Health Sciences Setagaya Tokyo 158-8501 Japan
3 shared publications
Latest Publications
- 13 October 2023
- Published by Wiley in Drug Testing and Analysis
- Vol. 16 (6) , 588-594
Structural analysis of an lysergic acid diethylamide (LSD) analogue N‐methyl‐N‐isopropyllysergamide (MiPLA): Insights from Rotamers in NMR spectra
Lysergic acid diethylamide (LSD) is a hallucinogenic compound that binds to and activates the serotonin 2A receptor and is classified as a controlled narcotic in Japan. Recently, MiPLA, an N‐methyl‐N‐isopropyl derivative of LSD, has been detected in paper‐sheet products in several countries. This study focuses on the synthesis of MiPLA and includes a comprehensive analysis involving structural and liquid chromatography–mass spectrometry (LC‐MS). Particularly, MiPLA was synthesized in three‐steps starting from ergometrine maleate, which resulted in the formation of (8S)‐isomer, iso‐MiPLA, as a by‐product. The LC‐MS results showed that LSD, MiPLA, and iso‐MiPLA exhibited different retention times. Their chemical structures were determined using nuclear magnetic resonance spectroscopy, which revealed the presence of rotamers involving the N‐methyl‐N‐isopropyl groups of tertiary amides in MiPLA and iso‐MiPLA.
- 13 October 2023
- Published by Wiley in Drug Testing and Analysis
- Vol. 16 (6) , 588-594
Structural analysis of an lysergic acid diethylamide (LSD) analogue N‐methyl‐N‐isopropyllysergamide (MiPLA): Insights from Rotamers in NMR spectra
Lysergic acid diethylamide (LSD) is a hallucinogenic compound that binds to and activates the serotonin 2A receptor and is classified as a controlled narcotic in Japan. Recently, MiPLA, an N‐methyl‐N‐isopropyl derivative of LSD, has been detected in paper‐sheet products in several countries. This study focuses on the synthesis of MiPLA and includes a comprehensive analysis involving structural and liquid chromatography–mass spectrometry (LC‐MS). Particularly, MiPLA was synthesized in three‐steps starting from ergometrine maleate, which resulted in the formation of (8S)‐isomer, iso‐MiPLA, as a by‐product. The LC‐MS results showed that LSD, MiPLA, and iso‐MiPLA exhibited different retention times. Their chemical structures were determined using nuclear magnetic resonance spectroscopy, which revealed the presence of rotamers involving the N‐methyl‐N‐isopropyl groups of tertiary amides in MiPLA and iso‐MiPLA.
- Open Access
- 25 February 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (3) , 34
Targeted Protein Degradation by Chimeric Compounds using Hydrophobic E3 Ligands and Adamantane Moiety
Targeted protein degradation using small chimeric molecules, such as proteolysis-targeting chimeras (PROTACs) and specific and nongenetic inhibitors of apoptosis protein [IAP]-dependent protein erasers (SNIPERs), is a promising technology in drug discovery. We recently developed a novel class of chimeric compounds that recruit the aryl hydrocarbon receptor (AhR) E3 ligase complex and induce the AhR-dependent degradation of target proteins. However, these chimeras contain a hydrophobic AhR E3 ligand, and thus, degrade target proteins even in cells that do not express AhR. In this study, we synthesized new compounds in which the AhR ligands were replaced with a hydrophobic adamantane moiety to investigate the mechanisms of AhR-independent degradation. Our results showed that the compounds, 2, 3, and 16 induced significant degradation of some target proteins in cells that do not express AhR, similar to the chimeras containing AhR ligands. However, in cells expressing AhR, 2, 3, and 16 did not induce the degradation of other target proteins, in contrast with their response to chimeras containing AhR ligands. Overall, it was suggested that target proteins susceptible to the hydrophobic tagging system are degraded by chimeras containing hydrophobic AhR ligands even without AhR.
- 25 February 2020
- Published by MDPI AG in Pharmaceuticals
- Vol. 13 (3) , 34
Open AccessTargeted Protein Degradation by Chimeric Compounds using Hydrophobic E3 Ligands and Adamantane Moiety
Targeted protein degradation using small chimeric molecules, such as proteolysis-targeting chimeras (PROTACs) and specific and nongenetic inhibitors of apoptosis protein [IAP]-dependent protein erasers (SNIPERs), is a promising technology in drug discovery. We recently developed a novel class of chimeric compounds that recruit the aryl hydrocarbon receptor (AhR) E3 ligase complex and induce the AhR-dependent degradation of target proteins. However, these chimeras contain a hydrophobic AhR E3 ligand, and thus, degrade target proteins even in cells that do not express AhR. In this study, we synthesized new compounds in which the AhR ligands were replaced with a hydrophobic adamantane moiety to investigate the mechanisms of AhR-independent degradation. Our results showed that the compounds, 2, 3, and 16 induced significant degradation of some target proteins in cells that do not express AhR, similar to the chimeras containing AhR ligands. However, in cells expressing AhR, 2, 3, and 16 did not induce the degradation of other target proteins, in contrast with their response to chimeras containing AhR ligands. Overall, it was suggested that target proteins susceptible to the hydrophobic tagging system are degraded by chimeras containing hydrophobic AhR ligands even without AhR.
- 1 November 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (20) , 5494-5498
Design and synthesis of cell-permeable fluorescent nitrilotriacetic acid derivatives
- 1 November 2018
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 26 (20) , 5494-5498
Design and synthesis of cell-permeable fluorescent nitrilotriacetic acid derivatives
- 1 July 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 24 (13) , 2914-2919
Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator
- 1 July 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 24 (13) , 2914-2919
Synthesis and evaluation of raloxifene derivatives as a selective estrogen receptor down-regulator
- 1 July 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (13) , 3091-3096
Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators
- 1 July 2015
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 23 (13) , 3091-3096
Synthesis and evaluation of tamoxifen derivatives with a long alkyl side chain as selective estrogen receptor down-regulators
- 1 January 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (1) , 87-89
Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator
- 1 January 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (1) , 87-89
Design and synthesis of tamoxifen derivatives as a selective estrogen receptor down-regulator
- 2 February 2011
- Published by Wiley in Drug Testing and Analysis
- Vol. 3 (9) , 594-596
Enzyme‐assisted synthesis of the glucuronide conjugate of psilocin, an hallucinogenic component of magic mushrooms
An enzyme‐assisted synthesis of psilocin glucuronide (PCG), a metabolite excreted in the urine of magic mushroom (MM) users, is described. In the presence of Aroclor 1254 pretreated rat liver microsomes, psilocin and the cofactor UDPGA were incubated for 20 h. Purification by HPLC gave PCG in 19% yield (3.6 mg). The compound structure was characterized by MS and NMR. The milligram amounts of PCG produced by this method will allow the direct identification and quantification of PCG in the urine of MM users. Copyright © 2011 John Wiley & Sons, Ltd.
- 2 February 2011
- Published by Wiley in Drug Testing and Analysis
- Vol. 3 (9) , 594-596
Enzyme‐assisted synthesis of the glucuronide conjugate of psilocin, an hallucinogenic component of magic mushrooms
An enzyme‐assisted synthesis of psilocin glucuronide (PCG), a metabolite excreted in the urine of magic mushroom (MM) users, is described. In the presence of Aroclor 1254 pretreated rat liver microsomes, psilocin and the cofactor UDPGA were incubated for 20 h. Purification by HPLC gave PCG in 19% yield (3.6 mg). The compound structure was characterized by MS and NMR. The milligram amounts of PCG produced by this method will allow the direct identification and quantification of PCG in the urine of MM users. Copyright © 2011 John Wiley & Sons, Ltd.
- 1 January 2009
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 57 (5) , 472-475
4-Hydroxy-3-methoxymethamphetamine Glucuronide as a Phase II Metabolite of 3,4-Methylenedioxymethamphetamine: Enzyme-Assisted Synthesis and Involvement of Human Hepatic Uridine 5'-Diphosphate-Glucuronosyltransferase 2B15 in the Glucuronidation
3,4-Methylenedioxymethamphetamine (MDMA), one of the most popular illicit recreational drugs, is metabolized primarily into 4-hydroxy-3-methoxymethamphetamine (HMMA) by drug-metabolizing enzymes. HMMA is further metabolized by phase II enzymes to give the glucuronide or sulfate which is excreted into urine. In the present study, enzyme kinetic studies with various microsomes showed that rat liver microsomes pretreated with Aroclor 1254 were most suitable for the enzyme-assisted synthesis of the glucuronide (HMMA-Gluc). This method selectively produced the β-anomer of HMMA-Gluc in a very high, isolated yield (71%), and with a purity that was sufficient for use in an analysis of MDMA intake and for enzyme kinetic studies. We also identified, by an LC-MS method, the human uridine 5′-diphosphate-glucuronosyltransferase (UGT) isoforms that catalyze the glucuronidation of HMMA. Among 12 isoforms of human recombinant UGT expressed in insect cells, UGT2B15 was the only isoform that showed adequate enzymatic activity in catalyzing HMMA glucuronidation with Km and Vmax values of 3.8 mM and 1.6 nmol/min/mg protein, respectively. The finding that UGT2B15 is capable of HMMA glucuronidation suggests this isoform may have an important in vivo role in human MDMA metabolism.
- 1 January 2009
- Published by Pharmaceutical Society of Japan in Chemical and Pharmaceutical Bulletin
- Vol. 57 (5) , 472-475
4-Hydroxy-3-methoxymethamphetamine Glucuronide as a Phase II Metabolite of 3,4-Methylenedioxymethamphetamine: Enzyme-Assisted Synthesis and Involvement of Human Hepatic Uridine 5'-Diphosphate-Glucuronosyltransferase 2B15 in the Glucuronidation
3,4-Methylenedioxymethamphetamine (MDMA), one of the most popular illicit recreational drugs, is metabolized primarily into 4-hydroxy-3-methoxymethamphetamine (HMMA) by drug-metabolizing enzymes. HMMA is further metabolized by phase II enzymes to give the glucuronide or sulfate which is excreted into urine. In the present study, enzyme kinetic studies with various microsomes showed that rat liver microsomes pretreated with Aroclor 1254 were most suitable for the enzyme-assisted synthesis of the glucuronide (HMMA-Gluc). This method selectively produced the β-anomer of HMMA-Gluc in a very high, isolated yield (71%), and with a purity that was sufficient for use in an analysis of MDMA intake and for enzyme kinetic studies. We also identified, by an LC-MS method, the human uridine 5′-diphosphate-glucuronosyltransferase (UGT) isoforms that catalyze the glucuronidation of HMMA. Among 12 isoforms of human recombinant UGT expressed in insect cells, UGT2B15 was the only isoform that showed adequate enzymatic activity in catalyzing HMMA glucuronidation with Km and Vmax values of 3.8 mM and 1.6 nmol/min/mg protein, respectively. The finding that UGT2B15 is capable of HMMA glucuronidation suggests this isoform may have an important in vivo role in human MDMA metabolism.